A look at the day ahead in European and global markets from Tom Westbrook After a few weeks buying the rumour of U.S.-China ...

Obesity drugmaker Novo Nordisk on Wednesday posted first-quarter operating profit above analyst forecasts and cut its ...

Treasury Secretary Scott Bessent and U.S. Trade Representative Jamieson Greer are traveling to Switzerland on Thursday to meet Beijing's lead economic representative, potentially paving the way for ...

With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention.

Shares of the company, which once boasted of media mogul Oprah Winfrey as one of its top shareholders, slumped 40% in ...

Pharmaceutical company Novo Nordisk is waiting on federal approval to sell its blockbuster GLP-1 weight-loss treatment as a pill.

Health-care companies fell due to regulatory fears. Shares of biotech firm Gilead Sciences, obesity-drug makers Eli Lilly, and Novo Nordisk were among the biggest losers amid reports that the Trump ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

Not long ago the largest company by market capitalization in Europe, the evolution of the weight loss medicine market has ...

Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...

The Rutgers Institute for Corporate Social Innovation recognized leaders who demonstrate the potential for business to ...

We recently published a list of 21 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Novo ...